structure rsv fusion glycoprotein trimer bound prefusion-specific neutralizing antibody
prefusion state respiratory syncytiat virus rsv fusion f glycoprotein target rsv-neutralizing activity human sera metastability hindered characterization overcome obstacle identified prefusion-specific antibodies substantially potent prophylactic antibody palivizumab cocrystal structure one antibodies d25 complex f glycoprotein revealed d25 lock f prefusion state binding quaternary epitope trimer apex electron microscopy showed two antibodies am22 5c4 also bound newly identified site vulnerability named antigenic site empty set studies enable design improved vaccine antigens define new targets passive prevention rsv-induced disease
